
GH — Guardant Health Inc
NASDAQ · Healthcare · Diagnostics & Research
$163.89
-$0.52 (-0.32%)
Guardant Health Inc (GH) is a diagnostics & research company listed on NASDAQ. It is led by Helmy Eltoukhy Ph.D., based in 3100 Hanover Street, Palo Alto, CA, United States, 94304, with about 1,999 employees. Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Latest reported GH revenue for 2025-09-30 was $265.2M. Net income was -$92.7M. Revenue was up 14.3% from 2025-06-30 to 2025-09-30. GH currently screens at market cap $6.32B.
Use this GH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GH SEC filings page. Lician reads the product cache first so this HTML stays unique to Guardant Health Inc even when a live quote feed is slow.
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
GH Key Statistics
Market Cap
$6.32B
Volume
1.19M
Previous Close
$163.18
Day Range
$161.22 – $167.90
EPS
-$3.56
Revenue
$739.02M
Net Income
-$436.37M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+31.0%
Profit Margin
-59.0%
Employees
1,999
GH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $739.02M | $563.95M | $449.54M | $373.65M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$436.37M | -$479.45M | -$654.59M | -$384.77M |
| EPS (Diluted) | -$3.56 | -$4.28 | -$6.41 | -$4.00 |
Total Assets
$1.49B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$525.54M
Operating Cash Flow
-$239.86M
Free Cash Flow
$0.00
Guardant Health Inc Company Information
- Co-Founder, Co-CEO & Chairman
- Helmy Eltoukhy Ph.D.
- Headquarters
- 3100 Hanover Street, Palo Alto, CA, United States, 94304
- Website
- guardanthealth.com
- Phone
- 855 698 8887
- IPO / Founded
- 2018-10-04
- Sector
- Healthcare
- Industry
- Diagnostics & Research